TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29577550

Group type: COMPARATOR
Intervention: ZGN-1061 (SAD phase, N=28)
Number of subjects: 39

Group type: COMPARATOR
Intervention: ZGN-1061 (MAD phase, N=22)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (SAD phase, N=11)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (MAD phase, N=7)
Number of subjects: 39
Study: 26602363

Group type: EXPERIMENTAL
Intervention: 12 weeks of lifestyle intervention (IIG)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Delayed start control group (DSCG)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups after 3 months of intensive intervention
Number of subjects: 62
Study: 25408736

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no physical activity intervention)
Number of subjects: 70
Study: 22116296

Group type: EXPERIMENTAL
Intervention: Non-invasive Masimo Hb (SpHb) measurement
Number of subjects: 50
Study: 21179732

Group type: EXPERIMENTAL
Intervention: Mild warming moxibustion (MWM) on acupoints Shenque (RN8) and Guanyuan (RN4) for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Intravenous dripping of immunoglobulin for 3 months (Control)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 17570902

Group type: EXPERIMENTAL
Intervention: SGA (risperidone or clozapine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: FGA
Number of subjects: 18
Study: 16188898

Group type: EXPERIMENTAL
Intervention: Low‐flux cuprammonium (CU) dialyser
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All dialyser modalities
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline levels in chronic HD patients
Number of subjects: 15
Study: 11870387

Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a (40 kd)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: interferon alfa‐2a
Number of subjects: 1441
Study: 12016811

Group type: EXPERIMENTAL
Intervention: IVIgG (100‐300 mg.kg‐1.d‐1) for 2‐3 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 54
Study: 7570325

Group type: EXPERIMENTAL
Intervention: Laparoscopic herniorrhaphy (LH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open hernia repair (OH)
Number of subjects: 0
Study: 1705274

Group type: EXPERIMENTAL
Intervention: 30 mg/day tamoxifen
Number of subjects: 38

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 38
Study: 7349450

Group type: EXPERIMENTAL
Intervention: Cotton pad impregnated with diverse secretions of the mother
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotton pad impregnated with secretions of another mother or a pad with no specific odour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olfactory recognition by mothers of their baby's odour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tee-shirt worn against the mother's skin for 2 to 3 days
Number of subjects: 0
Study: 31116114

Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 30

Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pre-oxygenation with CPAP 10 cmH2O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of oesophageal sphincter pressures pre-oxygenation vs after anaesthesia induction
Number of subjects: 30
Study: 27029939

Group type: EXPERIMENTAL
Intervention: Low cost home‐based virtual reality system for rehabilitation of the arm (8 weeks use)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study: 25908106

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (patients without comorbid anxiety)
Number of subjects: 148
Study: 23411616

Group type: EXPERIMENTAL
Intervention: Candesartan (n=602)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Standard medical therapy without candesartan (n=543)
Number of subjects: 1145
Study: 20094823

Group type: COMPARATOR
Intervention: Exhaled carbon monoxide (eCO) levels in asthmatic patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Exhaled carbon monoxide (eCO) levels in allergic rhinitis patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: HO-1 expression in asthmatic patients
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy in asthmatic patients
Number of subjects: 19
Study: 19232940

Group type: EXPERIMENTAL
Intervention: 15 mg of ephedrine per 20 mL of propofol (Group E15)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 30 mg of ephedrine per 20 mL of propofol (Group E30)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 1% lidocaine per 20 mL of 1% propofol (Group L)
Number of subjects: 156
Study: 17446700

Group type: EXPERIMENTAL
Intervention: Citrate-based CVVH
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nadroparin-based CVVH
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15385385

Group type: EXPERIMENTAL
Intervention: endotracheal lidocaine 160 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 11427213

Group type: EXPERIMENTAL
Intervention: avasimibe 50 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: avasimibe 125 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: avasimibe 250 mg
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: avasimibe 500 mg
Number of subjects: 130

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 130
Study: 9700115

Group type: EXPERIMENTAL
Intervention: Outreach educational program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 9441080

Group type: EXPERIMENTAL
Intervention: Chemotherapy (SCC) regimen
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Surgery plus chemotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 33
Study: 2008945

Group type: EXPERIMENTAL
Intervention: Isoflurane (2 MAC in 100% oxygen)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Halothane (2 MAC in 100% oxygen)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isoflurane (extubation after awakening)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Halothane (extubation after awakening)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Awake extubation (either agent)
Number of subjects: 100
Study: 6812143

Group type: EXPERIMENTAL
Intervention: Intravenous L-tryptophan (TRP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31371212

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) plus placebo
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus fluoxetine (20 mg daily)
Number of subjects: 153
Study: 28346003

Group type: EXPERIMENTAL
Intervention: 1% diclofenac sodium cream applied topically every 12 hours for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo cream applied topically every 12 hours for 7 days
Number of subjects: 12
Study: 26341769

Group type: EXPERIMENTAL
Intervention: Microsurgical subinguinal varicocelectomy with testicular delivery (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Microsurgical subinguinal varicocelectomy without testicular delivery (group 2)
Number of subjects: 100
Study: 24613047

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 22584619

Group type: EXPERIMENTAL
Intervention: Double-row technique
Number of subjects: 160

Group type: COMPARATOR
Intervention: Single-row technique
Number of subjects: 160
Study: 18667807

Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 17141859

Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol (400/12 mug)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Formoterol (12 mug)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide (400 mug)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All treatments (Budesonide/Formoterol, Formoterol, Budesonide)
Number of subjects: 15
Study: 15367427

Group type: EXPERIMENTAL
Intervention: Transfusion with a target dose of 0.5 x 10(11)/10 kg (arm A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Transfusion with a target dose of 1 x 10(11)/10 kg (arm B)
Number of subjects: 101
Study: 12538121

Group type: EXPERIMENTAL
Intervention: Allon thermoregulatory (AT) system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine thermal care (RTC)
Number of subjects: 60
Study: 9322459

Group type: EXPERIMENTAL
Intervention: Eltanolone (0.75 mg/kg i.v. for 18-60 yr or ASA I/II; 0.5 mg/kg i.v. for 61-80 yr or ASA III)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Eltanolone (1.0 mg/kg i.v. for 18-60 yr or ASA I/II; 0.75 mg/kg i.v. for 61-80 yr or ASA III)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Propofol (2.4 mg/kg i.v. for 18-60 yr or ASA I/II; 1.6 mg/kg i.v. for 61-80 yr or ASA III)
Number of subjects: 83
Study: 8229121

Group type: EXPERIMENTAL
Intervention: Dietary intervention group receiving a program of individualized instruction for reducing total fat intake
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Dietary intervention group
Number of subjects: 290

Group type: COMPARATOR
Intervention: Dietary control group with minimal dietary counseling
Number of subjects: 290
Study: 3753924

Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propantheline 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30036739

Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab, oxaliplatin and fluoropyrimidine
Number of subjects: 754
Study: 24977690

Group type: EXPERIMENTAL
Intervention: AEG35156 (300 mg weekly intravenous infusion) in combination with sorafenib (400 mg twice daily orally)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sorafenib alone (400 mg twice daily orally)
Number of subjects: 51
Study: 23995295

Group type: EXPERIMENTAL
Intervention: Couples HIV testing and counseling (CHTC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual voluntary HIV counseling and testing (iVCT)
Number of subjects: 0
Study: 22187070

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAC)
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Regular colonoscopy (CC)
Number of subjects: 1380
Study: 20620323

Group type: EXPERIMENTAL
Intervention: Transanal endorectal pull-through (TERP)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Transabdominal approach (TAA)
Number of subjects: 281
Study: 18552687

Group type: COMPARATOR
Intervention: Protocolized Sedation (PS)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Protocolized Sedation + Daily Interruption (PS + DI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Both groups (PS and PS + DI)
Number of subjects: 65
Study: 16002965

Group type: EXPERIMENTAL
Intervention: Sputum Induction (SI)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar Lavage (BAL)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ozone (O(3)) exposure
Number of subjects: 13

Group type: COMPARATOR
Intervention: Filtered Air (FA) exposure
Number of subjects: 13
Study: 12218525

Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (target plasma concentration 0.3 ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine (target plasma concentration 0.6 ng/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (both doses) during shivering
Number of subjects: 0
Study: 10507599

Group type: EXPERIMENTAL
Intervention: Dopexamine 0.5 microg/kg/min
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dopexamine 2.0 microg/kg/min
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8725976

Group type: EXPERIMENTAL
Intervention: Cholesterol Treatment Program (CTP)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Usual Health Care (UHC)
Number of subjects: 247
Study: 1890156

Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6731022

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 39

Group type: COMPARATOR
Intervention: Metrizoate
Number of subjects: 39
Study: 31099992

Group type: EXPERIMENTAL
Intervention: RD3 (dexmedetomidine at an initial dose of 0.5 μg/kg for 10 min adjusted to 0.6 μg kg−1 hr−1 throughout EIT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (sufentanil only)
Number of subjects: 86
Study: 29042172

Group type: EXPERIMENTAL
Intervention: Supervised upper limb program (SULP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No supervised upper limb program (NULP)
Number of subjects: 80
Study: 26689231

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS), consumed once a day for 8 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus casei strain Shirota (LcS)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo milk, consumed once a day for 8 weeks
Number of subjects: 47
Study: 25193490

Group type: EXPERIMENTAL
Intervention: Video administered at one month (early intervention)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Video administered at seven months (late intervention)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Both early and late intervention groups
Number of subjects: 105
Study: 22927525

Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m(2)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m(2) with paclitaxel 80 mg/m(2)
Number of subjects: 39
Study: 20496732

Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Baihui (GV 20) and Zusanli (ST 36)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Electroacupuncture at Taichong (LR 3), Sanyinjiao (SP 6), Neiguan (PC 6), and Shenmen (HT 7)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral administration of Fluoxetine
Number of subjects: 84
Study: 17623822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 15667868

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily (OD)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg OD
Number of subjects: 360
Study: 12218722

Group type: EXPERIMENTAL
Intervention: E/NETA 0.25-mg group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: E/NETA 0.5-mg group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 120
Study: 9795543

Group type: EXPERIMENTAL
Intervention: Medical self-care book and education session
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 7893027

Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine (0.2 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Lidocaine without epinephrine
Number of subjects: 7
Study: 2667629

Group type: EXPERIMENTAL
Intervention: Silicone rubber cup
Number of subjects: 258

Group type: COMPARATOR
Intervention: Metal vacuum extractor cups
Number of subjects: 258
Study: 1091959

Group type: EXPERIMENTAL
Intervention: Methyl prednisolone acetate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 0
Study: 31391073

Group type: EXPERIMENTAL
Intervention: Usual care plus Proactive Psychological Medicine (PPM)
Number of subjects: 3588

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 3588
Study: 28306329

Group type: EXPERIMENTAL
Intervention: Listening to music during office-based PNTP (Group I, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No music during office-based PNTP (Group II, n=50)
Number of subjects: 100
Study: 25421369

Group type: EXPERIMENTAL
Intervention: Aortobifemoral bypass surgery
Number of subjects: 78
Study: 22669692

Group type: EXPERIMENTAL
Intervention: Fipronil spot-on formulation (26.8 mg a.i./kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fipronil spot-on formulation (13.4 mg a.i./kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fipronil spray formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated dogs)
Number of subjects: 0
Study: 20394872

Group type: EXPERIMENTAL
Intervention: Digital reactive hyperemia peripheral arterial tonometry (RH‐PAT) measured using Endo‐PAT2000 before cardiac catheterization.
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: RH‐PAT index
Number of subjects: 140
Study: 18714458

Group type: EXPERIMENTAL
Intervention: Determine HIV‐1/2
Number of subjects: 324

Group type: COMPARATOR
Intervention: 4th generation ELISA (Vironostika HIV Uni‐Form II AG/Ab)
Number of subjects: 324
Study: 15730535

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 200 mg
Number of subjects: 12
Study: 12019586

Group type: EXPERIMENTAL
Intervention: Isokinetic dynamometry using a Biodex dynamometer (Multi joint system 2) at 60 degrees/second (5 repetitions), 120 degrees/second (10 repetitions), and 180 degrees/second (10 repetitions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two consecutive individual measurements
Number of subjects: 20
Study: 10343210

Group type: EXPERIMENTAL
Intervention: Sedation with midazolam for upper GI endoscopy
Number of subjects: 10

Group type: COMPARATOR
Intervention: No sedation (control group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sedation (control group) for patients without liver disease
Number of subjects: 10
Study: 8542895

Group type: EXPERIMENTAL
Intervention: Talcid (hydrotalcite 1 g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maalox (Mg‐Al‐hydroxide)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Talcid
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 16
Study: 1822599

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA) with 1.9 ml bupivacaine HCl 0.5%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Continuous epidural anesthesia (CEA) with 12.6 ml bupivacaine HCl 0.5%
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia (CSA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Continuous epidural anesthesia (CEA)
Number of subjects: 33
Study: 7010157

Group type: EXPERIMENTAL
Intervention: Timolol (10 mg twice daily)
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study: 29676346

Group type: EXPERIMENTAL
Intervention: Honey (H)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2.5% Formal Saline (FS)
Number of subjects: 43
Study: 25319752

Group type: EXPERIMENTAL
Intervention: Val homozygous adults
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: COMT Val158Met genotypes
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Network analyses
Number of subjects: 212
Study: 23864516

Group type: EXPERIMENTAL
Intervention: Customized pamphlets and home-exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Delayed-treatment contact group
Number of subjects: 30
Study: 21933812

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Motivation for change
Number of subjects: 74
Study: 19878298

Group type: EXPERIMENTAL
Intervention: Topical treatment with calcipotriol
Number of subjects: 0
Study: 18417354

Group type: EXPERIMENTAL
Intervention: Sun bed exposure (0.5 to 1 MED, twice per week for 4 weeks)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daily supplement of 200 IU vitamin D (cod liver oil capsules)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No vitamin D supplementation
Number of subjects: 10
Study: 16325084

Group type: EXPERIMENTAL
Intervention: Transfemoral fixation implant (Transfix; Arthrex) and interference screw (Arthrex) in the tibial tunnel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Extracortical fixation (EndoButton; Smith & Nephew) in the femur and bicortical screw and washer distal to the tibial tunnel
Number of subjects: 100
Study: 12687466

Group type: EXPERIMENTAL
Intervention: Daily calcitriol (10 ng/kg per day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intermittent calcitriol (35 ng/kg twice a week)
Number of subjects: 24
Study: 10227453

Group type: EXPERIMENTAL
Intervention: Triple drug regimen (TDR) with cyclophosphamide 200 mg/m2, methotrexate 20 mg/m2 once a week, and 6-mercaptopurine 50 mg/m2 daily
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oxymetholone (2 mg/m2/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Supportive therapy only
Number of subjects: 18
Study: 9172009

Group type: EXPERIMENTAL
Intervention: Tramadol (100‐mg slow‐release tablet every 8‐12 h)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Buprenorphine (0.2‐mg sublingual tablet every 6‐8 h)
Number of subjects: 131
Study: 1765729

Group type: EXPERIMENTAL
Intervention: piracetam
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 7159894

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 51

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 51
Study: 31166287

Group type: EXPERIMENTAL
Intervention: Preservative-free T2347
Number of subjects: 242

Group type: COMPARATOR
Intervention: BAK-preserved latanoprost-timolol fixed combination
Number of subjects: 242
Study: 28115006

Group type: EXPERIMENTAL
Intervention: Optimisation intervention to promote parent engagement in HENRY programme
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Optimisation intervention
Number of subjects: 144
Study: 26864655

Group type: EXPERIMENTAL
Intervention: Behavioral Activation and Therapeutic Exposure (BA-TE) delivered via Home-Based Telehealth (HBT)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Behavioral Activation and Therapeutic Exposure (BA-TE) delivered in person
Number of subjects: 232
Study: 24313619

Group type: EXPERIMENTAL
Intervention: Porcine placental extract (PPE), 3 capsules per day for 24 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Porcine placental extract (PPE), 3 capsules per day
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Porcine placental extract (PPE), 6 capsules per day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 44